Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04052425 |
|
Recruitment Status :
Recruiting
First Posted : August 9, 2019
Last Update Posted : March 2, 2020
|
Sponsor:
Incyte Corporation
Information provided by (Responsible Party):
Incyte Corporation
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Non-segmental Vitiligo | Drug: Ruxolitinib cream Drug: Vehicle | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 300 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Intervention Model Description: | Participants will receive ruxolitinib cream or vehicle for 24 weeks, after which they will be offered the opportunity to continue in the treatment extension period. Participants initially randomized to vehicle will be crossed over to active drug, and participants treated with ruxolitinib cream will receive an additional 28 weeks of treatment with ruxolitinib cream. |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo |
| Actual Study Start Date : | September 20, 2019 |
| Estimated Primary Completion Date : | April 16, 2021 |
| Estimated Study Completion Date : | November 30, 2021 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Vitiligo
MedlinePlus related topics:
Vitiligo
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Ruxolitinib cream
Ruxolitinib cream 1.5% twice daily (BID) for 24 weeks followed by ruxolitinib cream 1.5% BID for an additional 28-week treatment extension period.
|
Drug: Ruxolitinib cream
Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Other Name: INCB018424 cream |
|
Placebo Comparator: Vehicle
Vehicle cream for 24 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 28-week treatment extension period.
|
Drug: Vehicle
Vehicle cream is a topical formulation applied as a thin film to affected areas. |
Primary Outcome Measures :
- Proportion of participants achieving F-VASI75 [ Time Frame: Week 24 ]≥ 75% improvement from baseline in Face Vitiligo Area Scoring Index (F-VASI) score.
Secondary Outcome Measures :
- Percentage change from baseline in facial body surface area (F-BSA) [ Time Frame: Week 24 ]
- Proportion of participants achieving F-VASI50 [ Time Frame: Week 24 ]≥ 50% improvement from baseline in F-VASI score.
- Proportion of participants achieving F-VASI75 [ Time Frame: Week 52 ]≥ 75% improvement from baseline in F-VASI score.
- Proportion of participants achieving F-VASI90 [ Time Frame: Week 24 ]≥ 90% improvement from baseline in F-VASI score.
- Proportion of participants achieving F-VASI90 [ Time Frame: Week 52 ]≥ 90% improvement from baseline in F-VASI score.
- Proportion of participants achieving T-VASI50 [ Time Frame: Week 24 ]≥ 50% improvement in total body Vitiligo Area Scoring Index (T-VASI).
- Proportion of participants achieving T-VASI50 [ Time Frame: Week 52 ]≥ 50% improvement in T-VASI.
- Proportion of participants achieving T-VASI75 [ Time Frame: Week 52 ]≥ 75% improvement in T-VASI.
- Proportion of participants achieving a Vitiligo Noticeability Scale (VNS) of "4 - A lot less noticeable" or "5 - No longer noticeable" [ Time Frame: Week 24 ]
- Number of treatment-emergent adverse events [ Time Frame: Up to 56 weeks ]Any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.
- Proportion of participants achieving F-VASI25/50/75/90 [ Time Frame: During the treatment period (double-blind and treatment extension periods), up to 52 weeks. ]≥ 25%/ 50%/ 75%/90% improvement from baseline in F-VASI score.
- Percentage change from baseline in F-VASI [ Time Frame: From baseline to during the treatment period (double-blind and treatment extension periods), up to 52 weeks. ]
- Percentage change from baseline in F-BSA [ Time Frame: From baseline to during the treatment period (double-blind and treatment extension periods), up to 52 weeks. ]
- Percentage change from baseline in T-VASI [ Time Frame: From baseline to during the treatment period (double-blind and treatment extension periods), up to 52 weeks. ]
- Percentage change from baseline in total body surface area (T-BSA) [ Time Frame: From baseline to during the treatment period (double-blind and treatment extension periods), up to 52 weeks. ]
- Proportion of participants achieving T-VASI25/50/75/90 [ Time Frame: During the treatment period (double-blind and treatment extension periods), up to 52 weeks. ]≥ 25%/ 50%/ 75%/90% improvement in T-VASI.
- Proportion of participants in each category of VNS [ Time Frame: During the treatment period (double-blind and treatment extension periods), up to 52 weeks. ]
- Population-based (trough) plasma concentrations of ruxolitinib [ Time Frame: Week 4 ]
- Population-based (trough) plasma concentrations of ruxolitinib [ Time Frame: Week 24 ]
- Population-based (trough) plasma concentrations of ruxolitinib [ Time Frame: Week 40 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- Clinical diagnosis of non-segmental vitiligo with depigmented area including ≥ 0.5% BSA on the face, ≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, ≥ 3 T-VASI, and total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.
- Agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.
- Must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child for the duration of study participation.
Key Exclusion Criteria:
- No pigmented hair within any of the vitiligo areas on the face.
- Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor).
- Have used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas.
- Use of protocol-defined treatments within the indicated washout period before baseline.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04052425
Contacts
| Contact: Incyte Corporation Call Center (US) | 1.855.463.3463 | medinfo@incyte.com | |
| Contact: Incyte Corporation Call Center (ex-US) | +800 00027423 | globalmedinfo@incyte.com |
Locations
Show 60 study locations
Sponsors and Collaborators
Incyte Corporation
Investigators
| Study Director: | Kathleen Butler, MD | Incyte Corporation |
| Responsible Party: | Incyte Corporation |
| ClinicalTrials.gov Identifier: | NCT04052425 |
| Other Study ID Numbers: |
INCB 18424-306 |
| First Posted: | August 9, 2019 Key Record Dates |
| Last Update Posted: | March 2, 2020 |
| Last Verified: | February 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Incyte Corporation:
|
Vitiligo non-segmental JAK inhibitor |
Additional relevant MeSH terms:
|
Vitiligo Hypopigmentation Pigmentation Disorders Skin Diseases |